Faithward Advisors LLC Increases Position in Jazz Pharmaceuticals PLC $JAZZ

Faithward Advisors LLC raised its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 93.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 27,904 shares of the specialty pharmaceutical company’s stock after acquiring an additional 13,475 shares during the period. Faithward Advisors LLC’s holdings in Jazz Pharmaceuticals were worth $3,678,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Farther Finance Advisors LLC increased its holdings in shares of Jazz Pharmaceuticals by 754.8% in the third quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock valued at $35,000 after purchasing an additional 234 shares during the last quarter. Danske Bank A S acquired a new position in Jazz Pharmaceuticals during the third quarter worth $40,000. Quent Capital LLC acquired a new position in Jazz Pharmaceuticals during the third quarter worth $44,000. Geneos Wealth Management Inc. grew its holdings in Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 137 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its holdings in Jazz Pharmaceuticals by 1,383.3% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 332 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Jazz Pharmaceuticals

In related news, SVP Mary Elizabeth Henderson sold 5,343 shares of the stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $194.49, for a total transaction of $1,039,160.07. Following the completion of the transaction, the senior vice president owned 28,728 shares of the company’s stock, valued at approximately $5,587,308.72. This trade represents a 15.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Patricia Carr sold 1,287 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $182.94, for a total transaction of $235,443.78. Following the completion of the sale, the chief accounting officer owned 6,512 shares of the company’s stock, valued at $1,191,305.28. This trade represents a 16.50% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 68,015 shares of company stock valued at $13,037,486 in the last ninety days. Insiders own 4.30% of the company’s stock.

Analysts Set New Price Targets

JAZZ has been the topic of several analyst reports. Truist Financial lifted their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Piper Sandler reissued an “overweight” rating and issued a $219.00 price objective (up from $147.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, December 10th. Robert W. Baird raised their price objective on shares of Jazz Pharmaceuticals from $160.00 to $209.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 18th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research note on Monday, December 29th. Finally, Wells Fargo & Company increased their price target on shares of Jazz Pharmaceuticals from $235.00 to $250.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Thirteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $214.38.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ opened at $181.37 on Wednesday. The stock has a market cap of $11.17 billion, a PE ratio of -30.38, a P/E/G ratio of 0.33 and a beta of 0.22. The company has a current ratio of 1.86, a quick ratio of 1.67 and a debt-to-equity ratio of 1.00. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $198.00. The stock has a fifty day simple moving average of $172.77 and a 200-day simple moving average of $157.19.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.49 by $0.15. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The firm had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same period in the previous year, the firm earned $6.51 EPS. Jazz Pharmaceuticals’s revenue was up 8.1% on a year-over-year basis. Equities analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.